is an independent, causal, genetic risk factor for cardiovascular disease and aortic stenosis. Current pharmacological lipid-lowering therapies do not optimally lower Lp(a), particularly in patients with familial hypercholesterolemia (FH). Approach and Results-In 4 phase III trials, 382 patients on maximally tolerated lipid-lowering therapy were randomized 2:1 to weekly subcutaneous mipomersen 200 mg (n=256) or placebo (n=126) for 26 weeks. Populations included homozygous FH, heterozygous FH with concomitant coronary artery disease (CAD), severe hypercholesterolemia, and hypercholesterolemia at high risk for CAD. Lp(a) was measured 8× between baseline and week 28 inclusive. Of the 382 patients, 57% and 44% had baseline Lp(a) levels >30 and >50 mg/dL, respectively. In the pooled analysis, the mean percent decrease (median, interquartile range in Lp(a) at 28 weeks was significantly greater in the mipomersen group compared with placebo (−26.4 [−42.8, −5.4] versus −0.0 [−10.7, 15.3]; P<0.001). In the mipomersen group in patients with Lp(a) levels >30 or >50 mg/dL, attainment of Lp(a) values ≤30 or ≤50 mg/dL was most frequent in homozygous FH and severe hypercholesterolemia patients. In the combined groups, modest correlations were present between percent change in apolipoprotein B-100 and Lp(a) (r=0.43; P<0.001) and low-density lipoprotein cholesterol and Lp(a) (r=0.36; P<0.001) plasma levels. Conclusions-Mipomersen consistently and effectively reduced Lp(a) levels in patients with a variety of lipid abnormalities and cardiovascular risk. Modest correlations were present between apolipoprotein B-100 and Lp(a) lowering but the mechanistic relevance mediating Lp(a) reduction is currently unknown. (Arterioscler Thromb Vasc Biol. 2015;35:689-699. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
L ipoprotein(a) [Lp(a)] is composed of apolipoprotein(a) covalently bound to apolipoprotein B-100 (apoB) of lowdensity lipoprotein (LDL). 1, 2 Lp(a) levels vary substantially among individuals (<0.1->250 mg/dL) with minimal dietary or environmental effect and display a wide racial distribution, with highest levels in people of African and South Asian origin, followed by whites, Hispanics, and East Asians, respectively. [2] [3] [4] Approximately 30% of whites and 60% to 70% of blacks have what are considered elevated Lp(a) levels of >30 mg/dL. Recent epidemiological, genome-wide association, and Mendelian randomization studies strongly support the concept that Lp(a) is a causal, independent, genetic risk factor for myocardial infarction, stroke, peripheral arterial disease, and calcific aortic stenosis. [5] [6] [7] [8] [9] [10] [11] Lp(a) levels are elevated in patients with familial hypercholesterolemia (FH) compared with healthy individuals or unaffected family members and more so than would be predicted from LPA genotypes, such as number of KIV-2 repeats. 12 Elevated Lp(a) levels are a particularly strong and independent risk factor for cardiovascular disease (CVD) in this subgroup with concomitant elevation of LDL cholesterol (LDL-C). [12] [13] [14] [15] [16] [17] [18] Individuals with homozygous FH (HoFH) with 2 nonfunctional low-density lipoprotein receptor (LDLR) alleles have ≈2-fold higher levels of Lp(a) compared with heterozygous (HeFH) patients and higher risk of CVD. 12, 19 These data demonstrate a gene-dosage effect on Lp(a), despite the fact that human and murine turnover kinetic studies have failed to show that the LDLR is significantly involved in Lp(a) clearance, suggesting additional mechanisms for elevated levels. 20, 21 Established drug therapies to lower Lp(a) levels are essentially limited to niacin, although trials to assess clinical outcomes with niacin in patients with elevated Lp(a) levels have not been performed. In addition, lipoprotein apheresis is specifically approved in Germany for patients with progressive CVD, controlled LDL-C levels, and Lp(a) levels >60 mg/dL, and is used on an ad hoc basis in the United States and other countries. 22 With the established, independent clinical risk of elevated Lp(a) levels, 23 new treatments are needed to reduce CVD in these patients. Mipomersen is a second-generation antisense oligonucleotide directed to liver messenger RNA (mRNA) of apoB that reduces LDL-C. [24] [25] [26] [27] Because apoB is the essential structural component of all apoB-containing lipoproteins, including LDL, inhibition of apoB synthesis may reduce levels of all apoB-containing atherogenic lipoproteins, including Lp(a). In this study, we examined the effect of mipomersen on Lp(a) in 4 randomized, double-blind, placebo controlled phase III trials.
Materials and Methods
Materials and methods are available in the online-only Data Supplement.
Results

Trial Design
Data sets were obtained from phase III trials of mipomersen in 4 different populations, such as (1) HoFH (NCT00607373)genetic confirmation of HoFH or a clinical diagnosis based on an untreated LDL-C >500 mg/dL together with either xanthoma before 10 years of age or evidence of HeFH in both the parents 24 ; (2) severe hypercholesterolemia (NCT00794664)-diagnosis of severe hypercholesterolemia having an LDL-C ≥200 mg/dL 25 ; (3) HeFH with CAD (NCT00706849)-diagnosis of HeFH plus LDL-C ≥100 mg/dL and triglycerides <200 mg/dL and a diagnosis of CAD 26 ; and (4) hypercholesterolemia at high risk for CAD per National Cholesterol Education Program Adult Treatment Panel III guidelines (NCT00770146)-LDL-C ≥100 mg/dL with triglycerides <200 mg/dL. 27 All the 4 trials were conducted with the same study design ( Figure 1 ) at 26 clinical centers in 6 countries. Each trial randomized patients 2:1 to weekly, subcutaneous injections of mipomersen 200 mg or placebo for 26 weeks on a background of maximally tolerated lipid-lowering therapy.
Patient Characteristics
The primary end points from each trial were previously reported. [24] [25] [26] [27] Patient characteristics are shown in Table 1 and included 382 patients. Most patients were middle-aged (mean age, 53 years) and overweight (mean body mass index, 29 kg/ m 2 ), with 48.4% having metabolic syndrome and about one sixth being current smokers. HoFH patients were younger and tended to be leaner compared with the other groups.
Previous/concomitant lipid-lowering medications are shown in Table 2 . About one third of all patients were concomitantly taking a statin as monotherapy, another third were taking a statin plus niacin or ezetimibe or a combination of both, and another third were taking a combination of a statin and another lipid-lowering medication.
The cardiovascular history summary for patients enrolled in the phase III trials are shown in Table I in the online-only Data Supplement. In the HoFH population, about half of the patients had a history of CVD/procedures. The placebo and mipomersen groups were similar with respect to cardiovascular history.
Baseline Lp(a) Levels and Changes After Mipomersen Therapy
The distributions of baseline Lp(a) levels by individual study show that Lp(a) values are progressively shifted rightward to higher levels with the severity of hypercholesterolemia ( Figure 2) , relative to what is normally seen in unselected populations, such as in the Copenhagen studies. 28 Table 3 shows the baseline and percent change in Lp(a) during the 28 Figure 3 . A separation of the curves in the mipomersen versus placebo is evident in the pooled data analysis by week 5 and the curves continue to diverge until week 26. Similar changes were noted in all 4 individual trials. Figure 4 displays waterfall plots of individual patients for percent change in Lp(a) from baseline in the pooled analysis of all 4 trials. In the mipomersen group, a wide variability was noted in Lp(a) responses, with the greatest maximal reduction of −84.2% and the maximal increase was 97%. It is also noted that a few patients (10.5% total) in each study had increases in Lp(a), as a percent change from baseline, despite mipomersen treatment and many patients (46.0% total) had Lp(a) decreases in the placebo arm. Similar changes were noted in all 4 individual trials. It is to be emphasized that because of the broad distribution of baseline Lp(a) levels, small absolute changes in Lp(a), particularly in patients with low values, can be accentuated when analyzed as a percent change. The median and maximum % changes (increase and decrease) in Lp(a) for patients with baseline Lp(a) levels above 30 mg/dL was −28.2% (97% and −84.2%), respectively.
Percent of Patients Reaching Lp(a) Levels ≤30 and ≤50 mg/dL
It is generally accepted that elevated Lp(a) levels are defined as >30 or >75 nmol/L, which approximates the 75th percentile of the Framingham population. 29 In addition, the European Atherosclerosis Society suggested that optimal Lp(a) levels should be <50 mg/dL, which represents the 80th percentile of northern European populations. 28 On the basis of these parameters, we determined the percentage of patients reaching these goals as shown in Table 4 . At baseline, 64 (50.8%) placebo patients and 152 (59.4%) mipomersen patients had Lp(a) levels >30 mg/dL, and 56 (44.4%) placebo patients and 111 (43.4%) mipomersen patients had Lp(a) levels >50 mg/dL. In the mipomersen group after 26 weeks of treatment, 10.9% of patients shifted from having Lp(a) levels >30 mg/dL to levels ≤30 mg/dL. The greatest reductions to ≤30 mg/dL were present in the HoFH (26.5%) and severe hypercholesterolemia (15.4%) populations; smaller shifts were observed in the HeFH with CAD (8.5%) and hypercholesterolemia at high risk for CAD populations (5.9%). Similarly, 15.6% of patients having baseline Lp(a) >50 mg/ dL achieved Lp(a) ≤50 mg/dL on mipomersen, with the greatest shifts in the HoFH population (23.5%). Smaller shifts were observed in the severe hypercholesterolemia (12.8%), HeFH with CAD (15.9%) and in the hypercholesterolemia at high risk for CAD populations (13.9%). No patients in the placebo group with a baseline Lp(a) >30 mg/dL achieved ≤30 mg/dL; only 2.4% of patients in the placebo group having an Lp(a) >50 mg/dL achieved Lp(a) levels ≤50 mg/dL.
Correlations Between Changes in Lp(a) With Lipid and Lipoprotein Parameters
To address the question whether significant correlations existed between the baseline and % change in Lp(a) and lipid levels, Spearman correlations were generated in the mipomersen treated patients (Table 5 ). At baseline, Lp(a) levels were not correlated with total cholesterol (TC), apoB, LDL-C, highdensity lipoprotein cholesterol, and triglycerides. However, when evaluating the data as the percent change, modest but significant correlations were noted between the change in Lp(a) and the change in TC, apoB, and LDL-C. However, these correlations explain ≈5% to 15% of the relationship. Furthermore, correction of LDL-C for Lp(a) cholesterol content did not appreciably change these relationships. Figure 5 displays the correlations between the changes in Lp(a), apoB, and LDL-C in the mipomersen and placebo groups. As expected, there was a strong linear correlation between percent reduction in LDL-C and apoB levels before and after treatment (r=0.95; P<0.001) during 26 weeks. However, only modest correlations were noted between percent change in apoB and Lp(a) (r=0.43; P<0.001) and LDL-C and Lp(a) (r=0.36; P<0.001), respectively.
Predictors of the Change in Lp(a) Levels
The relationship between baseline patient characteristics and effect of mipomersen in Lp(a) lowering was assessed by Table 6 ). This analysis reveals that the only factors predicting >median % change were white race, lower baseline TC, and LDL-C levels, and particularly lower achieved % change in TC and LDL-C levels. Other baseline variables and medications did not predict change in Lp(a) levels.
Discussion
This pooled analysis of 4 phase III randomized trials shows that mipomersen consistently lowers plasma Lp(a) levels by a median of 26.4% compared with placebo. This was shown across various groups of patients with different causes of hypercholesterolemia, including patients with HoFH and HeFH who had Lp(a) levels that were 2-to 3-fold higher than non-FH patients. In the mipomersen-treated group, a wide variability was noted in Lp(a)-lowering responses. Modest correlations were present between apoB and Lp(a) lowering but the mechanistic relevance to Lp(a) lowering of this observation is currently unknown.
On the basis of a large number of epidemiological, genomewide association, and Mendelian randomization studies, Lp(a) is generally considered an independent, causal, genetic risk factor for CVD and calcific aortic stenosis. 1, 2, 5, 6, 10, 17, [30] [31] [32] [33] [34] [35] [36] In fact, in the genome-wide association studies, its relationship with CAD is as strong, if not stronger, than other lipid and inflammatory genes. 33 Lp(a) confers cardiovascular risk through its LDL moiety and through its proatherogenic, proinflammatory, and potentially prothrombotic properties, which may be due, in part to the oxidized phospholipids bound to Lp(a). In addition, Lp(a) can induce macrophage apoptosis, a key factor in plaque vulnerability. [37] [38] [39] [40] [41] [42] A randomized trial of Lp(a) lowering to assess clinical outcomes has not been performed to date, mainly because of the lack of specific or effective therapies. The European Atherosclerosis Society and the National Lipid Association recommend screening for elevated Lp(a) in patients with CVD, recurrent events, family history of premature CVD, and high to intermediate risk for CVD. 28, [43] [44] [45] These recommendations were reinforced by the results of a recent prospective, observational study performed specifically in patients with elevated Lp(a) (>60 mg/dL) on lipid-lowering medications and previous history of CVD, showing that apheresis prevented the recurrence of major atherosclerotic events. 22 Hence, it is generally recommended that patients with FH were screened for elevated Lp(a) levels. 46 Although there are no randomized trials to support it, the European Atherosclerosis Society recommends that desirable levels of Lp(a) should be under the 80th percentile, or ≤50 mg/dL.
The wide variability in baseline plasma Lp(a) levels, as noted here in all 4 trials, is mainly because of the LPA gene. 2 The variability in plasma Lp(a) levels is attributed to (1) polymorphic differences in kringle IV-type 2 repeats, of which there are >40 isoforms (≈25% to 50%), (2) single-nucleotide polymorphisms in coding and noncoding sequences that can increase or decrease Lp(a) levels (≈30% to 40%), and (3) undefined mechanisms (≈10%). In addition, the LPA gene is under transcriptional regulation by a variety of factors, such as the estrogen and farnesoid X receptors, transforming growth factor, interleukin-6, and fibroblast growth factor that may increase or decrease plasma levels under physiological or pathophysiologic conditions. 47 Interestingly, in the placebo group, there was also significant variability on repeat testing. The day-to-day or seasonal variability of Lp(a) levels has not been well studied, but levels seem to fluctuate around a genetically determined level. Lp(a) is an acute-phase reactant and levels may increase acutely 50% to 100%, such as during Other LLT(s) without Statin 0 0
Lipid-lowering medications started before, and continued into, the treatment period. The treatment period spans the time during which the study treatment is administered until the later of the primary efficacy time point and 14 days beyond the last study medication date. CAD indicates coronary artery disease, HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; and LLT, lipid-lowering therapy.
percutaneous intervention or after acute myocardial infarction. [48] [49] [50] Low-fat diets, 51,52 garlic supplements, 53, 54 and different types and doses of statins may exert modest increases in Lp(a), [55] [56] [57] [58] [59] including in children with HeFH, 60 although these findings are not entirely consistent.
Plasma Lp(a) concentrations are largely determined by lipoprotein synthesis rather than clearance. 2 The LDLR does not seem to play a significant role in Lp(a) catabolism but this has only been studied in small numbers of patients and in mice that do not have the LPA gene. 12, 20, 21 A large number of studies show an LDLR gene-dose effect on Lp(a) levels in patients with FH, [12] [13] [14] [15] [16] [17] [18] as also noted here. A priori, this might suggest that defective clearance of LDL, which underlies the metabolic defect in HoFH or HeFH, would also be responsible for elevated Lp(a) levels seen in these subjects. However, this contradicts the in vivo turnover studies in humans and mice 20, 21 that demonstrate that the LDLR is not directly involved with Lp(a) clearance. Interestingly, a reanalysis of these data suggests that the fractional catabolic rate of Lp(a) may be slightly reduced in HoFH patients, however, this does not seem to explain the significantly elevated Lp(a) levels in FH patients. 12 Alternative mechanisms must be operative to explain the high Lp(a) levels in subjects with defective or null LDLR mutations. 19 Apo(a) is covalently linked with apoB of LDL to form a mature Lp(a). However, it is not established if Lp(a) is formed within the hepatocyte, as suggested recently by an in vivo kinetic study, 61 or at the hepatocyte surface after the independent secretion of apo(a) and LDL, or even formed in the circulation by secreted free apo(a) binding to LDL. 2 Mipomersen acts by specifically binding to apoB mRNA in the hepatocyte, thus reducing translation and synthesis of apoB. As a consequence, mipomersen reduces hepatic apoB synthesis and consequently LDL formation. 24, 26 We speculate that a reduced pool of LDL particles (in the hepatocyte, at the surface or even in plasma) would then lead to decreased formation of Lp(a), although the site, or sites (in the hepatocyte, at the surface or even in plasma), at which this occurs remains to be determined. Insight into this suggested scheme comes from studies, in which mipomersen was administered to Lp(a) transgenic mice that express both human apoB-100 and human apo(a). Mipomersen profoundly lowered hepatic apoB-100 synthesis and plasma apoB-100 levels in these mice. Importantly, mipomersen reduced circulating Lp(a) levels by ≈75%. 62 However, hepatic apo(a) mRNA and plasma apo(a) levels were not significantly reduced, suggesting that reduced availability of newly synthesized apoB was rate limiting in inhibiting generation of Lp(a) particles in PET indicates primary efficacy timepoint. this murine model. By analogy to humans, the mipomerseninduced inhibition of hepatic apoB synthesis may have led to the lack of availability of a specific pool of apoB in the form of newly synthesized LDL in the hepatocyte, or on the hepatocyte surface, or even in plasma, thus limiting generation of Lp(a) particles, which would be translated to reduced plasma Lp(a) levels. Alternative methods to lower Lp(a) in these high-risk patients may include directly targeting Lp(a). In a recently completed phase I study, 63 dose-dependent mean reductions of Lp(a) 78%, and their associated proinflammatory oxidized phospholipids, 64 were present with ISIS-APO(a) Rx targeting apolipoprotein(a). The major predictors of the change in Lp(a) >median were white race and lower baseline, and particularly a lower percent change in LDL-C in response to mipomersen. For example, in the pooled data, patients with >median Lp(a) reductions, had a 25.2% decrease in LDL-C, whereas those with ≤median Lp(a) had a 39.4% reductions in LDL-C. Furthermore, no correlations were noted at baseline between Lp(a) and TC, LDL-C, highdensity lipoprotein cholesterol, but correlations existed in the percent change of these variables. This suggests that the effect of mipomersen on LDL-C and Lp(a) lowering may be interrelated through common pathways. Additional studies are necessary to further elucidate the mechanisms by which Lp(a) is synthesized and catabolized, which should help to clarify how mipomersen reduces plasma Lp(a) levels in humans. LDL-C and Lp(a) are independently and additively associated with the risk of CVD. This is especially valid for HoFH and HeFH where both lipoproteins are elevated in comparison with normolipidemic individuals. Mipomersen has been approved in the United States, as an adjunct to lipid-lowering medications and diet to reduce LDL-C, apoB, TC, and nonhigh-density lipoprotein cholesterol in patients with HoFH. Although mipomersen has not been evaluated in reducing CVD, other studies of LDL lowering in patients with HoFH and HeFH, such as apheresis and statin therapy, have shown a reduction in CVD events. 65 In addition, elevated Lp(a) levels are an independent predictor of CVD in men and women with FH, particularly those with a receptor-negative mutation in LDLR gene. 19 The Lp(a)-lowering effect of mipomersen, along with the LDL-C reduction, may favorably affect CVD risk in this high-risk population. 66 The preponderance of data, to date, support the concept that Lp(a) represents a potential target for further reducing overall CVD risk, 67 but whether the pharmacological lowering of Lp(a) reduces CVD risk remains to be proved. Current pharmacological lipid-lowering therapies, except niacin, generally do not lower Lp(a). 67 In fact, statins that increase LDLR expression either have a neutral or Lp(a) raising effect. 37 Niacin reduces Lp(a) by 20% to 30% in a dose-dependent manner. 67 Apheresis is the most efficacious treatment available to reduce Lp(a) (≤75% acutely and ≈35% in time-averaged Lp(a) reduction). 68 PCSK9 inhibitors and CETP (cholesteryl ester transfer protein) inhibitors in clinical trials also lower Lp(a) by 25% to 40%, also by unknown mechanisms. A specific antisense oligonucleotide to apo(a) was recently shown to reduce plasma Lp(a) levels in a phase I study in normal volunteers 78%. 63 Clinical trials of these novel agents that lower Lp(a) by new mechanisms may allow testing of the hypothesis that lowering Lp(a) levels may further reduce CVD risk. Determining whether lowering plasma Lp(a) is effective in reducing CVD events is one of the major challenges for improved treatment and prevention of CVD.
